Connect your AI

Mesa Laboratories MLAB Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

3MMMM

$248M-4.2%

Charles River LaboratoriesCRL

$65.32M+123%

RevvityRVTY

——

Fulgent Genetics, Inc.FLGT

——

Other financials

Income statement

Revenue$63.7M+2.6%

Gross profit$31.2M-0.5%

Operating income-$664.0K+85.5%

Net income$3.6M+317%

EPS (diluted)-$0.10+63.0%

Balance sheet

Cash & equivalents$26.9M-1.4%

Total debt$78.7M-53.1%

Total equity$186.2M+16.5%

Total assets$427.7M-1.3%

Cash flow

Operating cash flow$14.0M+10.2%

CapEx$417.0K-44.9%

Free cash flow$13.5M+13.7%

Valuation

Market cap$542.27M+3.7%

Enterprise value$594.05M-10.4%

P/S2.2×0.0×

Profitability

Gross margin56.8%—

Operating margin2.3%—

Net margin1.5%+0.8pp

FCF margin15.9%-1.8pp

Returns & leverage

Return on equity2.2%+1.1pp

Debt / equity0.4×-0.6×

Current ratio1.7×+1.1×

Where this comes from

Reported directly by Mesa Laboratories in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mesa Laboratories's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Mesa Laboratories's increase (decrease) in accounts receivable?: Mesa Laboratories (MLAB) reported increase (decrease) in accounts receivable of $4.13M in Q1 2026.
How has Mesa Laboratories's increase (decrease) in accounts receivable changed year-over-year?: Mesa Laboratories's increase (decrease) in accounts receivable increased by 36.8% year-over-year, from $3.02M to $4.13M.